Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb is conducting a study titled A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL). The study aims to assess the safety and effectiveness of BMS-986458, a new drug targeting B-cell lymphoma 6, in patients with relapsed or refractory non-Hodgkin lymphoma.
Intervention/Treatment: The study tests BMS-986458 both as a standalone treatment and in combination with other anti-lymphoma drugs like Rituximab, Glofitamab/Obinutuzumab, and Mosunetuzumab. These interventions aim to improve treatment outcomes for patients with challenging lymphoma cases.
Study Design: This interventional study is randomized and follows a single-group model without masking, focusing on treatment as its primary purpose. The study is divided into different parts, assessing BMS-986458 alone and in combination with other drugs.
Study Timeline: The study began on October 13, 2023, with an estimated completion date of October 20, 2025. These dates are crucial for tracking progress and anticipating results that could influence treatment protocols and market dynamics.
Market Implications: The ongoing study by Bristol-Myers Squibb could significantly impact its stock performance, especially if the results are favorable. Success in this study may enhance investor confidence and position the company competitively within the oncology market, where advancements in lymphoma treatment are highly valued.
The study is currently recruiting, with further details available on the ClinicalTrials portal.